DK0565549T3 - Anvendelse af 1,3-oxathiolannucleosidanaloger til fremstilling af et præparat til behandling af hepatitis B - Google Patents

Anvendelse af 1,3-oxathiolannucleosidanaloger til fremstilling af et præparat til behandling af hepatitis B

Info

Publication number
DK0565549T3
DK0565549T3 DK92901354.8T DK92901354T DK0565549T3 DK 0565549 T3 DK0565549 T3 DK 0565549T3 DK 92901354 T DK92901354 T DK 92901354T DK 0565549 T3 DK0565549 T3 DK 0565549T3
Authority
DK
Denmark
Prior art keywords
preparation
hepatitis
treatment
oxathiolannucleoside
analogues
Prior art date
Application number
DK92901354.8T
Other languages
Danish (da)
English (en)
Inventor
Bernard Belleau
Nghe Nguyen-Ba
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0565549(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919100039A external-priority patent/GB9100039D0/en
Priority claimed from GB919109913A external-priority patent/GB9109913D0/en
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Application granted granted Critical
Publication of DK0565549T3 publication Critical patent/DK0565549T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK92901354.8T 1991-01-03 1992-01-03 Anvendelse af 1,3-oxathiolannucleosidanaloger til fremstilling af et præparat til behandling af hepatitis B DK0565549T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919100039A GB9100039D0 (en) 1991-01-03 1991-01-03 Medicaments
GB919109913A GB9109913D0 (en) 1991-05-07 1991-05-07 Medicaments

Publications (1)

Publication Number Publication Date
DK0565549T3 true DK0565549T3 (da) 1995-07-03

Family

ID=26298202

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92901354.8T DK0565549T3 (da) 1991-01-03 1992-01-03 Anvendelse af 1,3-oxathiolannucleosidanaloger til fremstilling af et præparat til behandling af hepatitis B

Country Status (23)

Country Link
US (2) USRE39155E1 (zh)
EP (2) EP0494119A1 (zh)
JP (1) JP2659863B2 (zh)
KR (1) KR0156747B1 (zh)
AT (1) ATE120644T1 (zh)
AU (1) AU660650B2 (zh)
CA (2) CA2254613A1 (zh)
CY (1) CY2047B1 (zh)
DE (1) DE69201948T2 (zh)
DK (1) DK0565549T3 (zh)
EE (1) EE02995B1 (zh)
ES (1) ES2070628T3 (zh)
GE (1) GEP19981482B (zh)
GR (1) GR3015694T3 (zh)
HK (1) HK159395A (zh)
IE (1) IE73642B1 (zh)
IL (1) IL100502A (zh)
MD (1) MD1224C2 (zh)
NO (1) NO180407C (zh)
PH (1) PH31397A (zh)
TJ (1) TJ249B (zh)
TW (1) TW202385B (zh)
WO (1) WO1992011852A1 (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
US5932635A (en) * 1991-07-30 1999-08-03 Cytec Technology Corp. Tackified prepreg systems
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
CA2171550C (en) 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
WO1996012716A1 (en) * 1994-10-22 1996-05-02 Chong Kun Dang Corp. Nucleoside derivatives and process for preparing thereof
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
GB9517022D0 (en) * 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
ID19490A (id) 1996-06-25 1998-07-16 Glaxo Group Ltd Kombinasi-kombinasi antiviral
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US20030100532A1 (en) * 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
AU6898498A (en) 1997-04-07 1998-10-30 Triangle Pharmaceuticals, Inc. Use of mkc-442 in combination with other antiviral agents
ES2579903T3 (es) 1998-08-10 2016-08-17 Centre National De La Recherche Scientifique (Cnrs) Beta-L-2'-desoxi-nucleósidos para el tratamiento de la hepatitis B
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
ATE408410T1 (de) * 1998-11-02 2008-10-15 Gilead Sciences Inc Kombinationstherapie zur behandlung von hepatitis b infektionen
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CA2788498C (en) 2001-03-01 2016-02-16 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
EP1536804A4 (en) 2002-06-28 2007-10-31 Idenix Cayman Ltd 2'-C-METHYL-3'-O-L-VALINESTER-RIBOFURANOSYLCYTIDINE FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
ES2547002T3 (es) 2002-09-13 2015-09-30 Novartis Ag Beta-L-2' desoxinucleósidos para el tratamiento de cepas de VHB resistentes
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US8481554B2 (en) 2009-05-27 2013-07-09 Hetero Research Foundation Solid oral dosage forms of lamivudine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE108794T1 (de) * 1985-05-15 1994-08-15 Wellcome Found Therapeutische nucleoside und deren herstellung.
CA1327000C (en) * 1987-08-07 1994-02-15 David L.J. Tyrrell Antiviral therapy for hepatitis b
US5039667A (en) * 1987-08-07 1991-08-13 The Governors Of The University Of Alberta Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucleosides
US4997926A (en) * 1987-11-18 1991-03-05 Scripps Clinic And Research Foundation Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
JP2578501B2 (ja) * 1989-03-03 1997-02-05 キヤノン株式会社 電子写真用帯電部材
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
AU5659990A (en) * 1989-05-15 1990-12-18 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Method of treatment of hepatitis
JPH04501857A (ja) * 1989-05-15 1992-04-02 アメリカ合衆国 肝炎の治療方法
DK0479822T3 (da) * 1989-06-27 2000-03-20 Wellcome Found Terapeutiske nucleosider
NZ234534A (en) * 1989-07-17 1994-12-22 Univ Birmingham Pyrimidine 4'-thionucleoside derivatives and their preparation; intermediates therefor
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
KR910007655A (ko) * 1989-10-03 1991-05-30 엠. 피. 잭슨 치료용 뉴클레오시드
IE74701B1 (en) * 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
PT95516A (pt) * 1989-10-06 1991-08-14 Wellcome Found Processo para a preparacao de derivados de 2',3'-didesoxi nucleosidos 6-substituidos
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ATE143016T1 (de) * 1990-11-13 1996-10-15 Iaf Biochem Int Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
AU662130B2 (en) * 1991-03-06 1995-08-24 Emory University Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B
GB9105899D0 (en) * 1991-03-20 1991-05-08 Wellcome Found Therapeutic nucleosides
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments

Also Published As

Publication number Publication date
DE69201948T2 (de) 1995-08-03
IE920004A1 (en) 1992-07-15
CA2100269C (en) 1999-02-23
MD1224B2 (en) 1999-05-31
USRE39155E1 (en) 2006-07-04
CA2254613A1 (en) 1992-07-04
WO1992011852A1 (en) 1992-07-23
IL100502A (en) 1995-12-08
JPH06507150A (ja) 1994-08-11
TJ249B (en) 1999-12-23
GR3015694T3 (en) 1995-07-31
EP0565549A1 (en) 1993-10-20
KR0156747B1 (en) 1998-11-16
NO932442D0 (no) 1993-07-05
EP0494119A1 (en) 1992-07-08
PH31397A (en) 1998-10-29
EP0565549B1 (en) 1995-04-05
HK159395A (en) 1995-10-20
AU1153492A (en) 1992-08-17
NO180407B (no) 1997-01-06
MD1224C2 (ro) 1999-11-30
NO932442L (no) 1993-08-26
TW202385B (zh) 1993-03-21
US5532246A (en) 1996-07-02
IL100502A0 (en) 1992-09-06
ES2070628T3 (es) 1995-06-01
GEP19981482B (en) 1998-12-25
IE73642B1 (en) 1997-06-18
NO180407C (no) 1997-04-16
MD950086A (ro) 1997-01-31
CY2047B1 (en) 1998-04-30
CA2100269A1 (en) 1992-07-04
AU660650B2 (en) 1995-07-06
JP2659863B2 (ja) 1997-09-30
DE69201948D1 (de) 1995-05-11
ATE120644T1 (de) 1995-04-15
EE02995B1 (et) 1997-06-16

Similar Documents

Publication Publication Date Title
DK0565549T3 (da) Anvendelse af 1,3-oxathiolannucleosidanaloger til fremstilling af et præparat til behandling af hepatitis B
FI914928A0 (fi) Hydroximetyl (metylencyklopentyl) puriner och -pyrimidiner.
DK0453127T3 (da) Behandling af katarakt med 15-keto-prostaglandinforbindelser
DE19875016I2 (de) Nukleosidanalogen enthaltende Antiviren-Zubereitungen.
DK132188D0 (da) Anvendelse af tetrahydrobenz(c,d)indol-6-carboxamider som anxiolytika
DK0424156T3 (da) Behandling af hepatobiliær sygdom med 15-ketoprostaglandinforbindelser
FI911138A (fi) Ny substituerad aminfoerening och foerfarande foer dess framstaellning.
DK0388049T3 (da) Penciclovirderivater til behandling af hepatitis B infektioner
DK0430551T3 (da) Behandling af hjertedysfunktion med 15-keto-prostaglandinforbindelser
DK0454429T3 (da) Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
DK0469782T3 (da) Behandling af katarakt med prostacyclinforbindelser
ES2073871T3 (es) Tiazolidin-2,4-dionas en el tratamiento de la hipertension.
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
ES2093051T3 (es) Purinil- y pirimidil-tetrahidrofuranos.
FI941850A0 (fi) Uusi yhdiste, joka on leustroduksiini H, sen valmistus ja terapeuttinen käyttö
ES2057741T3 (es) Uso de un derivado de benzo(b)tiofeno-2-carboximidamida.
DK653687D0 (da) Middel til behandling af nyresygdomme